OncoSec Medical Inc (ONCSQ)

[furbush87]

JJ,
When looking at data on the Melanoma trials, the CR,PR, and ORR, are not significant compared to other treatments, what is significant is that their is documentation of increased TIL, CD8+, and other immune markers. I expect the expanded study will have better ORR, but what I want to see is even more increase in TIl etc.
There is enough now to support the P2B theory with a big pharma, especially in combination with mouse studies. The only question is what deal will they offer.

As to what Pazzo was told, I assume it was similar to what I was told, not that more trials were needed, but that ONCS was waiting on more events, I assume that means P2 final at a minimum, maybe even interim on the expanded study.